But the January 2026 Rybelsus-Ozempic Drug Label Still Has No Warnings for NAION Vision Loss Side Effect

(Posted by Tom Lamb at Drug Injury Watch)

The “Revised: 1/2026” Prescribing Information document for “RYBELSUS and OZEMPIC tablets” caused some initial confusion because while Rybelsus pills have been available in the US for more than five years, there are currently no brand-name pills called Ozempic available in the US. Despite the impending name change of Novo Nordisk semaglutide-containing pills from Rybelsus to Ozempic (more about this below), the semaglutide NAION risk remains. But the relatively recent “new” combined Rybelsus/Ozempic drug label still does not include any warnings about this non-arteritic anterior ischemic optic neuropathy, or NAION, vision loss side effect.

So that we do not get anything wrong about this soon-to-be name change from Rybelsus to Ozempic for Novo Nordisk semaglutide-containing pills, we direct you to this February 4, 2026, Novo Nordisk USA announcement, “Novo Nordisk introduces Ozempic® Pill; Available in the US Q2 2026“.

Now returning to the Rybelsus and Ozempic (semaglutide) NAION risk, and why it seems there should be a warning for this NAION vision loss side effect by now, we start by directing you to our February 13, 2026, post, “Risk of NAION With Semaglutide Medicines is 2 Times Higher Than SGLT2i Diabetes Drugs“.

And you can get more information about this still-emerging drug safety issue in our October 22, 2025, post, “Wegovy and Ozempic Increase NAION Risk, an Eye Side Effect That Can Result in Blindness“.

We have been covering semaglutide NAION risk involving Ozempic and Rybelsus, as well as Wegovy, since July 2024, when the first medical articles appeared linking those Novo Nordisk semaglutide drugs to an increased risk of this NAION vision loss side effect.

As pointed out above, when their “Revised: 1/2026” Prescribing Information document for “RYBELSUS and OZEMPIC tablets” was issued in late January 2026, the Novo Nordisk drug labels for Ozempic, Rybelsus, and Wegovy still did not include any NAION vision loss side-effect warnings.

Novo Nordisk’s failure to warn the doctors who are prescribing Ozempic, Rybelsus, and Wegovy — as well as their failure to warn the people who are using these popular semaglutide medicines — about the increased risk of NAION has resulted in drug injury lawsuits being filed against this pharmaceutical company on behalf of people diagnosed with non-arteritic anterior ischemic optic neuropathy, or NAION.

A person diagnosed with NAION while using one of those Novo Nordisk semaglutide medicines who may be interested in filing a drug injury lawsuit for legal compensation can submit an Ozempic / Wegovy / Rybelsus Vision Loss Case Evaluation Form online. It is free, confidential, and there is no obligation.

In the alternative, if you have a possible Wegovy, Rybelsus, or Ozempic (semaglutide) NAION drug injury lawsuit that you want evaluated by drug injury attorney Tom Lamb, you can send an email to TJL@LambLawOffice.com or call 910-256-2971.

DrugInjuryLaw.com: Medical & Legal Information About Drug Side Effects

Drug Injury Case Evaluation – Free. Confidential. No Obligation.